004_1024-X-350

FDA approved therapeutic indication is-

Erinlar (ceritinib LDK378) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.